Table 2

 Matched odds ratios of peripheral neuropathy associated with exposure to each lipid lowering drug one year before the index date. Province of Varese, Italy, 1997–1999

CasesControlsUnadjustedAdjusted
Number (%)Number (%)OR†(95% CI)†OR†(95% CI)†
†Odds ratios, and 95% confidence intervals, estimated including exposure to each lipid lowering drug as covariate in a model of conditional logistic regression. Estimates are unadjusted and adjusted for the presence of thyroid disease, diabetes, anaemia, chronic renal failure, and connective tissue disease. *p<0.05.
Lipid lowering drugs121 (5.93)1600 (4.44)1.36*(1.12 to 1.65)1.27*(1.05 to 1.55)
Statins95 (4.66)1334 (3.70)1.27*(1.02 to 1.58)1.22*(1.03 to 1.45)
    Pravastatin25 (1.23)313 (0.87)1.42(0.94 to 2.15)1.31(0.86 to 1.98)
    Fluvastatin5 (0.25)68 (0.19)1.36(0.54 to 3.38)1.24(0.49 to 3.12)
    Atorvastatin21 (1.03)436 (1.21)0.85(0.54 to 1.32)0.78(0.50 to 1.23)
    Simvastatin49 (2.40)811 (2.25)1.05(0.78 to 1.42)1.02(0.76 to 1.37)
Fibrates33 (1.62)340 (0.94)1.72*(1.19 to 2.48)1.54*(1.07 to 2.23)
    Bezafibrate11 (0.54)130 (0.36)1.41(0.75 to 2.65)1.29(0.69 to 2.42)
    Fenofibrate11 (0.54)112 (0.31)1.75(0.94 to 3.28)1.56(0.83 to 2.92)
    Gemfibrozil12 (0.59)141 (0.39)1.54(0.85 to 2.79)1.34(0.74 to 2.44)
Bile acid sequestrants1 (0.05)25 (0.07)0.79(0.11 to 5.88)0.55(0.07 to 4.20)